A basic study for controlling postmenopausal osteoporosis by targeting HIF1 alpha in osteoclasts

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10490
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Orthopaedic surgery
• Research Institution: Keio University
• Principal Investigator: Sato Yuiko 慶應義塾大学, 医学部(信濃町), 研究員 (70445443)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 骨粗鬆症

Outline of Final Research Achievements

Estrogen deficiency due to menopause is one of the most serious risks for osteoporosis development. We previously identified that HIF1α expressed in osteoclasts was a target for postmenopausal osteoporosis therapy. In the current study, we clarified that Raloxifene, Bazedoxifene, Tamoxifen and ED71, all of which are currently used for postmenopausal osteoporosis therapy, had HIF1α inhibiting activity in osteoclasts. We also demonstrated that HIF1α was expressed in osteoclasts under an androgen deficient condition in male osteoporosis model mice. We showed that decreased bone mineral density in androgen deficient male osteoporosis model mice was clearly blocked by administrating either Raloxifene, Bazedoxifene, Tamoxifen or ED71.

Free Research Field

骨代謝